Aspira Women’s Health (NASDAQ:AWH) Receives Neutral Rating from Cantor Fitzgerald

Aspira Women’s Health (NASDAQ:AWH)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report released on Wednesday, Benzinga reports. They currently have a $3.30 price objective on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 2.48% from the company’s current price.

Separately, StockNews.com raised Aspira Women’s Health from a “sell” rating to a “hold” rating in a research report on Wednesday, April 3rd.

Aspira Women’s Health Price Performance

Shares of Aspira Women’s Health stock opened at $3.22 on Wednesday. Aspira Women’s Health has a one year low of $2.31 and a one year high of $6.75. The firm has a market capitalization of $39.73 million, a price-to-earnings ratio of -0.27 and a beta of 1.61. The business has a 50-day simple moving average of $3.88 and a 200 day simple moving average of $4.14.

Institutional Trading of Aspira Women’s Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Aspira Women’s Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 196,007 shares of the company’s stock worth $800,000 after purchasing an additional 13,162 shares in the last quarter. Atria Wealth Solutions Inc. increased its holdings in Aspira Women’s Health by 42.1% during the 2nd quarter. Atria Wealth Solutions Inc. now owns 67,151 shares of the company’s stock worth $39,000 after purchasing an additional 19,900 shares in the last quarter. Quantum Private Wealth LLC increased its holdings in Aspira Women’s Health by 76.8% during the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock worth $205,000 after purchasing an additional 21,788 shares in the last quarter. Northeast Financial Consultants Inc bought a new position in shares of Aspira Women’s Health in the third quarter valued at approximately $126,000. Finally, Northern Trust Corp grew its holdings in shares of Aspira Women’s Health by 227.7% in the fourth quarter. Northern Trust Corp now owns 36,049 shares of the company’s stock valued at $147,000 after acquiring an additional 25,047 shares in the last quarter. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.